FDA Accepts CSL Behring’s BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks Full Year Results Announced 2016

30-August-2016 — CSL today announced that the FDA has accepted for review CSL Behring’s BLA for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent HAE attacks. More.

Full Year Result 2016
CSL Delivers Another Strong Performance

Full Year Results Announced 2016

17-August-2016 — CSL Limited today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016. “2016 has been a transformational year for CSL,” said CSL CEO and MD Paul Perreault. More.


Other recent news:

17-August-2016— Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 Sep 2016. Mr John Akehurst, has indicated his intention to retire at the conclusion of the Company’s AGM on 12 Oct 2016. More.
4-July-2016— CSL will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland. More.
10-June-2016 — Last night CSL Behring’s Australian facility was awarded ‘2016 Victorian Manufacturer of the Year’ at the Victorian Manufacturing Hall of Fame Awards. More.

© 2016 CSL Limited